CDMO supply chains “are potentially the biggest single risk to product resilience, yet they remain an area often overlooked by drug sponsors in partnering criteria”, said Bikash Chatterjee, CEO of Pharmatech Associates during a panel entitled ‘Redesigning the Supply Chain – The Road to Increased Resilience’. This was held as part of the online element of CPHI North America.